2022 | September / October 2022

Streamlining analytical method development with a focus on genotoxic impurities – Developing analytical methods for a range of genotoxic impurities

by cyb2025

MATTHEW WEBBERLEY
Associate Director, Analytical Research and Development, SK biotek Ireland, SK pharmteco Company, Swords, Ireland

ABSTRACT

Development of chromatographic methods for the determination of genotoxic (GTI) or potential genotoxic (PGI) impurities can be time consuming and laborious. Having a generic approach to a method development strategy can aid in the generation of a suitable method in a shorter space of time. Several different approaches to method development are possible. This paper provides an overview of method development strategies to generate a suitable, reliable, robust, and even validatable method for the determination of genotoxic impurities. The discussion includes several examples of successfully developed and validated methods for a range of genotoxic impurities, including nitrosamines, by liquid chromatography (LC) and gas chromatography (GC).

INTRODUCTION
The development of chromatographic methods to determine potential genotoxic impurities (GTIs) can be time consuming and laborious. While there are several approaches to method development (1), having a generic method development strategy can help streamline the process. This article provides an overview of method development strategies to help analysts, chromatographers, and researchers develop suitable, reliable, robust, and potentially validatable methods to determine GTIs. It includes several examples of successfully developed and validated methods for a range of GTIs, including nitrosamines, by liquid chromatography (LC) and gas chromatography (GC).

ABOUT THE AUTHOR

Matthew Webberley has 25 years of experience in the pharmaceutical and CDMO industry. He has experience in developing and validating a broad range of chromatographic and mass spectrometer based methods. Matthew gained his Doctorate in Organic Chemistry at Exeter University, UK and then as a Postdoctoral researcher at the Dyson Perrins Laboratory, University of Oxford, UK before joining the pharmaceutical sector.

Login